{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:50Z","timestamp":1785886790187,"version":"3.56.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Ther"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s40744-024-00693-y","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T00:02:52Z","timestamp":1722038572000},"page":"1217-1235","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A\u00a0Post Hoc Analysis of ORAL Surveillance"],"prefix":"10.1007","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct02092467","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3999-8093","authenticated-orcid":false,"given":"Bogdan","family":"Batko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Slawomir","family":"Jeka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9999-0267","authenticated-orcid":false,"given":"Piotr","family":"Wiland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Zieli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stopi\u0144ska-Polaszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3939-7194","authenticated-orcid":false,"given":"Marcin","family":"Stajszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kosydar-Piechna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jane","family":"Cadatal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6736-3962","authenticated-orcid":false,"given":"Jose L.","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,26]]},"reference":[{"key":"693_CR1","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/S0140-6736(16)30173-8","volume":"388","author":"JS Smolen","year":"2016","unstructured":"Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023\u201338.","journal-title":"Lancet"},{"key":"693_CR2","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S0140-6736(10)60826-4","volume":"376","author":"DL Scott","year":"2010","unstructured":"Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet. 2010;376:1094\u2013108.","journal-title":"Lancet"},{"key":"693_CR3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.acvd.2010.03.007","volume":"103","author":"C Meune","year":"2010","unstructured":"Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis. 2010;103:253\u201361.","journal-title":"Arch Cardiovasc Dis"},{"key":"693_CR4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","volume":"37","author":"J van den Hoek","year":"2017","unstructured":"van den Hoek J, Boshuizen HC, Roorda LD, et al. Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study. Rheumatol Int. 2017;37:487\u201393.","journal-title":"Rheumatol Int"},{"key":"693_CR5","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11883-014-0435-z","volume":"16","author":"E Golia","year":"2014","unstructured":"Golia E, Limongelli G, Natale F, et al. Inflammation and cardiovascular disease: from pathogenesis to therapeutic target. Curr Atheroscler Rep. 2014;16:435.","journal-title":"Curr Atheroscler Rep"},{"key":"693_CR6","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/art.41752","volume":"73","author":"L Fraenkel","year":"2021","unstructured":"Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2021;73:1108\u201323.","journal-title":"Arthritis Rheumatol"},{"key":"693_CR7","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","volume":"79","author":"JS Smolen","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79:685\u201399.","journal-title":"Ann Rheum Dis"},{"key":"693_CR8","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis. 2017;76:17\u201328.","journal-title":"Ann Rheum Dis"},{"key":"693_CR9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","volume":"381","author":"GR Burmester","year":"2013","unstructured":"Burmester GR, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381:451\u201360.","journal-title":"Lancet"},{"key":"693_CR10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","volume":"367","author":"R Fleischmann","year":"2012","unstructured":"Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495\u2013507.","journal-title":"N Engl J Med"},{"key":"693_CR11","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-159-4-201308200-00006","volume":"159","author":"J Kremer","year":"2013","unstructured":"Kremer J, Li Z-G, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159:253\u201361.","journal-title":"Ann Intern Med"},{"key":"693_CR12","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S, et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014;370:2377\u201386.","journal-title":"N Engl J Med"},{"key":"693_CR13","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/art.40803","volume":"71","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Strand V, Tanaka Y, et al. Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study. Arthritis Rheumatol. 2019;71:878\u201391.","journal-title":"Arthritis Rheumatol"},{"key":"693_CR14","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum. 2013;65:559\u201370.","journal-title":"Arthritis Rheum"},{"key":"693_CR15","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","volume":"367","author":"RF van Vollenhoven","year":"2012","unstructured":"van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508\u201319.","journal-title":"N Engl J Med"},{"key":"693_CR16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0140-6736(17)31618-5","volume":"390","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390:457\u201368.","journal-title":"Lancet"},{"key":"693_CR17","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","volume":"41","author":"J Wollenhaupt","year":"2014","unstructured":"Wollenhaupt J, Silverfield J, Lee EB, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41:837\u201352.","journal-title":"J Rheumatol"},{"key":"693_CR18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13075-016-0932-2","volume":"18","author":"H Yamanaka","year":"2016","unstructured":"Yamanaka H, Tanaka Y, Takeuchi T, et al. Tofacitinib, an oral Janus kinase inhibitor, as monotherapy or with background methotrexate, in Japanese patients with rheumatoid arthritis: an open-label, long-term extension study. Arthritis Res Ther. 2016;18:34.","journal-title":"Arthritis Res Ther"},{"key":"693_CR19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J, Lee EB, Curtis JR, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21:89.","journal-title":"Arthritis Res Ther"},{"key":"693_CR20","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2022-222586","volume":"81","author":"K Lauper","year":"2022","unstructured":"Lauper K, Iudici M, Mongin D, et al. Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the \u201cJAK-pot\u201d collaboration. Ann Rheum Dis. 2022;81:1358\u201366.","journal-title":"Ann Rheum Dis"},{"key":"693_CR21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"693_CR22","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/ard-2022-223715","volume":"82","author":"LE Kristensen","year":"2023","unstructured":"Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023;82:901\u201310.","journal-title":"Ann Rheum Dis"},{"key":"693_CR23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/ard-2022-222259","volume":"82","author":"C Charles-Schoeman","year":"2023","unstructured":"Charles-Schoeman C, Buch MH, Dougados M, et al. Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Ann Rheum Dis. 2023;82:119\u201329.","journal-title":"Ann Rheum Dis"},{"key":"693_CR24","unstructured":"Sowada C, Sagan A, Kowalska-Bobko I. Poland: health system summary, 2022. 2022. https:\/\/eurohealthobservatory.who.int\/publications\/i\/poland-health-system-summary. Accessed 23 Apr 2024."},{"key":"693_CR25","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1007\/s00439-002-0728-0","volume":"110","author":"R Ploski","year":"2002","unstructured":"Ploski R, Wozniak M, Pawlowski R, et al. Homogeneity and distinctiveness of Polish paternal lineages revealed by Y chromosome microsatellite haplotype analysis. Hum Genet. 2002;110:592\u2013600.","journal-title":"Hum Genet"},{"key":"693_CR26","doi-asserted-by":"crossref","unstructured":"Kaja E, Lejman A, Sielski D, et al. The Thousand Polish Genomes-A database of Polish variant allele frequencies. Int J Mol Sci. 2022;23:4532.","DOI":"10.3390\/ijms23094532"},{"key":"693_CR27","first-page":"591","volume":"18","author":"A Finckh","year":"2022","unstructured":"Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol. 2022;18:591\u2013602.","journal-title":"Nat Rev Rheumatol"},{"key":"693_CR28","doi-asserted-by":"crossref","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","volume":"6","author":"SB Cohen","year":"2020","unstructured":"Cohen SB, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6:e001395.","journal-title":"RMD Open"},{"key":"693_CR29","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1002\/art.40911","volume":"71","author":"C Charles-Schoeman","year":"2019","unstructured":"Charles-Schoeman C, DeMasi R, Valdez H, et al. Risk factors for major adverse cardiovascular events in Phase III and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:1450\u20139.","journal-title":"Arthritis Rheumatol"},{"key":"693_CR30","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim S, Lee H, Lee SB, Desai R. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81:798\u2013804.","journal-title":"Ann Rheum Dis"},{"key":"693_CR31","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/art.38894","volume":"67","author":"A Souto","year":"2015","unstructured":"Souto A, Salgado E, Maneiro JR, Mera A, Carmona L, G\u00f3mez-Reino JJ. Lipid profile changes in patients with chronic inflammatory arthritis treated with biologics and tofacitinib in randomized clinical trials: a systematic review and meta-analysis. Arthritis Rheumatol. 2015;67:117\u201327.","journal-title":"Arthritis Rheumatol"},{"key":"693_CR32","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s10067-023-06587-8","volume":"42","author":"G Gerganov","year":"2023","unstructured":"Gerganov G, Georgiev T, Dimova M, Shivacheva T. Vascular effects of biologic and targeted synthetic antirheumatic drugs approved for rheumatoid arthritis: a systematic review. Clin Rheumatol. 2023;42:2651\u201376.","journal-title":"Clin Rheumatol"},{"key":"693_CR33","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1007\/s00296-017-3844-9","volume":"37","author":"K Kume","year":"2017","unstructured":"Kume K, Amano K, Yamada S, et al. Tofacitinib improves atherosclerosis despite up-regulating serum cholesterol in patients with active rheumatoid arthritis: a cohort study. Rheumatol Int. 2017;37:2079\u201385.","journal-title":"Rheumatol Int"},{"key":"693_CR34","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1136\/annrheumdis-2018-214846","volume":"78","author":"W Xie","year":"2019","unstructured":"Xie W, Huang Y, Xiao S, Sun X, Fan Y, Zhang Z. Impact of Janus kinase inhibitors on risk of cardiovascular events in patients with rheumatoid arthritis: systematic review and meta-analysis of randomised controlled trials. Ann Rheum Dis. 2019;78:1048\u201354.","journal-title":"Ann Rheum Dis"},{"key":"693_CR35","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40744-018-0097-3","volume":"5","author":"S Cohen","year":"2018","unstructured":"Cohen S, Curtis JR, DeMasi R, et al. Worldwide, 3-year, post-marketing surveillance experience with tofacitinib in rheumatoid arthritis. Rheumatol Ther. 2018;5:283\u201391.","journal-title":"Rheumatol Ther"},{"key":"693_CR36","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s13075-015-0728-9","volume":"17","author":"TA Simon","year":"2015","unstructured":"Simon TA, Thompson A, Gandhi KK, Hochberg MC, Suissa S. Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis. Arthritis Res Ther. 2015;17:212.","journal-title":"Arthritis Res Ther"},{"key":"693_CR37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/canjclin.56.2.69","volume":"56","author":"D Schottenfeld","year":"2006","unstructured":"Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J Clin. 2006;56:69\u201383.","journal-title":"CA Cancer J Clin"},{"key":"693_CR38","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0300-483X(02)00612-1","volume":"185","author":"T Vial","year":"2003","unstructured":"Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology. 2003;185:229\u201340.","journal-title":"Toxicology"},{"key":"693_CR39","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.cjca.2016.04.008","volume":"32","author":"CB Johnson","year":"2016","unstructured":"Johnson CB, Davis MK, Law A, Sulpher J. Shared risk factors for cardiovascular disease and cancer: implications for preventive health and clinical care in oncology patients. Can J Cardiol. 2016;32:900\u20137.","journal-title":"Can J Cardiol"},{"key":"693_CR40","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3322\/caac.21703","volume":"72","author":"F Islami","year":"2022","unstructured":"Islami F, Guerra CE, Minihan A, et al. American Cancer Society\u2019s report on the status of cancer disparities in the United States, 2021. CA Cancer J Clin. 2022;72:112\u201343.","journal-title":"CA Cancer J Clin"},{"key":"693_CR41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cegh.2019.12.014","volume":"8","author":"U Religioni","year":"2020","unstructured":"Religioni U. Cancer incidence and mortality in Poland. Clin Epidemiol Glob Health. 2020;8:329\u201334.","journal-title":"Clin Epidemiol Glob Health"},{"key":"693_CR42","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.rdc.2016.09.008","volume":"43","author":"P Sivaraman","year":"2017","unstructured":"Sivaraman P, Cohen SB. Malignancy and Janus kinase inhibition. Rheum Dis Clin North Am. 2017;43:79\u201393.","journal-title":"Rheum Dis Clin North Am"},{"key":"693_CR43","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/acr2.11232","volume":"3","author":"JM Kremer","year":"2021","unstructured":"Kremer JM, Bingham CO, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 2021;3:173\u201384.","journal-title":"ACR Open Rheumatol"},{"key":"693_CR44","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/annrheumdis-2020-218992","volume":"80","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Citera G, Gold D, et al. Age-based (<65 vs \u226565 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry. Ann Rheum Dis. 2021;80:134\u20136.","journal-title":"Ann Rheum Dis"},{"key":"693_CR45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","volume":"17","author":"V Strand","year":"2015","unstructured":"Strand V, Ahadieh S, French J, et al. Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362.","journal-title":"Arthritis Res Ther"},{"key":"693_CR46","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.1016\/S2665-9913(19)30137-7","volume":"2","author":"A Pawar","year":"2020","unstructured":"Pawar A, Desai RJ, Gautam N, Kim SC. Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study. Lancet Rheumatol. 2020;2:E84-98.","journal-title":"Lancet Rheumatol"},{"key":"693_CR47","doi-asserted-by":"crossref","unstructured":"Ma\u0144ko A, Raczkiewicz A, G\u00f3rski A, Borysowski J, Wiland P. Exclusion of older adults from randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford). 2024;63:672\u20139.","DOI":"10.1093\/rheumatology\/kead257"},{"key":"693_CR48","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","volume":"69","author":"MJL Peters","year":"2010","unstructured":"Peters MJL, Symmons DPM, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69:325\u201331.","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00693-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40744-024-00693-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40744-024-00693-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T17:43:33Z","timestamp":1737395013000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40744-024-00693-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["693"],"URL":"https:\/\/doi.org\/10.1007\/s40744-024-00693-y","relation":{},"ISSN":["2198-6576","2198-6584"],"issn-type":[{"value":"2198-6576","type":"print"},{"value":"2198-6584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]},"assertion":[{"value":"16 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Bogdan Batko has speaking contracts, clinical trial contracts, and\/or has acted as a consultant for AbbVie, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli\u00a0Lilly, Janssen, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz, Sobi, and UCB. Slawomir Jeka has acted as a consultant for AbbVie, AstraZeneca, Celgene, Egis, Eli Lilly, Gilead, Medac, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz, Sobi, and UCB. Piotr Wiland has speaking contracts, clinical trial contacts, and\/or has acted as a consultant for AbbVie, AstraZeneca, Bristol Myers Squibb, Janssen, Medac, Novartis, Pfizer, and Sandoz. Agnieszka Zieli\u0144ska and Maria Stopi\u0144ska-Polaszewska have nothing to disclose. Marcin Stajszczyk has speaking contracts, clinical trial contracts, and\/or has acted as consultant for AbbVie,\u00a0Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli\u00a0Lilly, Janssen, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Sandoz, Swedish Orphan Biovitrum, and UCB. Magdalena Kosydar-Piechna, Mary Jane Cadatal, and Jose L Rivas are employees and shareholders of Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"ORAL Surveillance was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines of the International Council for Harmonisation, and was approved by the Institutional Review Board and\/or Independent Ethics Committee at each center (Supplementary Material). Patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}